Edition:
United States

Tocagen Inc (TOCA.OQ)

TOCA.OQ on NASDAQ Stock Exchange Global Select Market

11.00USD
15 Dec 2017
Change (% chg)

$-0.88 (-7.41%)
Prev Close
$11.88
Open
$11.50
Day's High
$11.81
Day's Low
$10.92
Volume
1,110,394
Avg. Vol
53,014
52-wk High
$17.75
52-wk Low
$8.64

Chart for

About

Tocagen Inc. (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to... (more)

Overall

Beta: --
Market Cap(Mil.): $217.90
Shares Outstanding(Mil.): 19.81
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Tocagen Q3 loss per share $0.50

* Tocagen reports third quarter 2017 financial and business results

Nov 08 2017

BRIEF-Tocagen to accelerate Toca 511 & Toca FC development into Phase 3 trial

* Tocagen to accelerate Toca 511 & Toca FC development into pivotal Phase 3 trial Source text for Eikon: Further company coverage:

Oct 26 2017

BRIEF-Tocagen Q2 loss per share $0.56

* Tocagen reports second quarter 2017 financial and business results

Aug 09 2017

BRIEF-Tocagen reports quarterly loss per share $0.56‍​

* Qtrly license revenue $10,000 versus $13,000 Source text: (http://bit.ly/2wuNluv) Further company coverage:

Aug 09 2017

BRIEF-Tocagen receives PRIME designation for Toca 511

* Tocagen receives European Medicines Agency Priority Medicines (PRIME) designation for Toca 511 in high grade Glioma Source text for Eikon: Further company coverage:

Jul 24 2017

Earnings vs. Estimates